The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia.

The psilocybin batch was purchased by Reset Mind Sciences Ltd., a Western Australian-based subsidiary of ASX-listed Little Green Pharma (LGP) that received ethics committee approval to forward a clinical trial on psilocybin-assisted therapy protocols for patients with treatment-resistant, Major Depressive Disorder (MDD.)

In view of Australia’s recent policy change regarding psychedelics-assisted therapy, other companies have offered supply agreements with on-site R&D or …

Full story available on